Results 1 to 10 of about 118,755 (255)

XXV Congresso Brasileiro de Cefaleia

Headache Medicine, 2011
IHS Masters School 1º Brazilian-North American Synposium (BRANAS) VI Congresso do Comitê de Dor ...
Headache Medicine
doaj   +3 more sources

XXXII CONGRESSO BRASILEIRO DE CEFALEIA / XIII CONGRESSO DE DOR OROFACIAL

Headache Medicine, 2018
XXXII CONGRESSO BRASILEIRO DE CEFALEIA / XIII CONGRESSO DE DOR ...
Headache Medicine
doaj   +3 more sources

Effects of galcanezumab on acute medication use and health care resource utilization in treatment-resistant migraine: results from randomized, double blind, placebo-controlled clinical trial, conquer

Headache Medicine, 2020
Introduction Acute headache medication use (AHM) and health care resource utilization (HCRU) in patients with protocol-defined treatment-resistant migraine treated with galcanezumab (GMB).
Anna Ambrosini, Emad Estemalik, Julio Pascual, Mallikarjuna Rettiganti, Chad Stroud, Kathleen Day, Janet Ford   +6 more
doaj   +1 more source

Summary of free themes / Abstracts - Headache and Orofacial Pain

Headache Medicine, 2017
XXXI Congresso Brasileiro de Cefaleia e XII Congresso de dor ...
Headache Medicine
doaj   +1 more source

XXVI Congresso Brasileiro de Cefaleia

Headache Medicine, 2012
Temas Livres - Apresentação de pôsteres Cefaleia e Dor ...
Headache Medicine
doaj   +1 more source

Early and Delayed Rebound Intracranial Hypertension following Epidural Blood Patch in a Case of Spontaneous Intracranial Hypotension

Case Reports in Neurological Medicine, 2022
Background. Spontaneous intracranial hypotension (SIH) is a secondary headache that has been attributed to a cerebrospinal fluid (CSF) leak. It may resolve spontaneously or require conservative treatment.
Elham Jafari, Maryam Karaminia, Mansoureh Togha   +2 more
doaj   +1 more source

Greater Occipital Nerve Block with Local Anesthetics and Corticosteroids in Treatment-Resistant Chronic Migraine

Headache Medicine, 2021
Objective: We investigated the efficacy and tolerability of greater occipital nerve block with lidocaine plus betamethasone in adults with chronic migraine in whom two or more previous preventive treatments were unsuccessful.
Vlasta Vukovic Cvetkovic, Roberto De Icco, Thien Phu Do, Lanfranco Pellesi, Messoud Ashina, Jakob Møller Hansen   +5 more
doaj   +1 more source

Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study

The Journal of Headache and Pain, 2021
Background Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway represent the first disease-specific preventive migraine therapy.
Bottiroli Sara, Roberto De Icco, Gloria Vaghi, Stefania Pazzi, Elena Guaschino, Marta Allena, Natascia Ghiotto, Daniele Martinelli, Cristina Tassorelli, Grazia Sances   +9 more
doaj   +1 more source

Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?

The Journal of Headache and Pain, 2020
Background Migraine can manifest with an episodic or a chronic pattern in a continuum of disease severity. Multiple factors are associated with the progression of the pattern from episodic to chronic.
Rosaria Greco, Roberto De Icco, Chiara Demartini, Anna Maria Zanaboni, Elena Tumelero, Grazia Sances, Marta Allena, Cristina Tassorelli   +7 more
doaj   +1 more source

Trajectory of blood pressure after initiating anti-calcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration

The Journal of Headache and Pain, 2023
Background Calcitonin gene-related peptide (CGRP) is involved in migraine pathophysiology and blood pressure regulation. Although clinical trials have established the cardio-cerebrovascular safety profile of anti-CGRP treatment, limited high-quality real-
Kaicheng Wang, Brenda T. Fenton, Vinh X. Dao, Alexander B. Guirguis, Sarah E. Anthony, Melissa Skanderson, Jason J. Sico   +6 more
doaj   +1 more source